See the DrugPatentWatch profile for Segluromet
Segluromet is a medication used to manage type 2 diabetes [1]. It combines two active ingredients: metformin and sitagliptin [1].
What is Segluromet and how does it work?
Segluromet is a dual-acting diabetes medication. Metformin works by decreasing the amount of glucose produced by the liver and by increasing the sensitivity of muscle cells to insulin, allowing them to take up more glucose from the blood. Sitagliptin belongs to a class of drugs called DPP-4 inhibitors. It works by increasing the levels of incretin hormones, which help to regulate blood sugar levels by increasing insulin secretion and decreasing glucagon secretion [1].
What is the difference between Segluromet and Janumet?
Both Segluromet and Janumet are combination medications for type 2 diabetes that contain metformin. However, Segluromet contains sitagliptin, while Janumet contains sitagliptin. These are essentially the same medication with different brand names [1].
When was Segluromet approved and when does its patent expire?
Information regarding the specific approval date and patent expiry for Segluromet is not readily available in the provided text. Patent information for specific drugs can be found through resources like DrugPatentWatch.com [2].
What are the potential side effects of Segluromet?
Common side effects of Segluromet can include diarrhea, nausea, vomiting, abdominal pain, and loss of appetite, which are often associated with metformin. Other potential side effects related to sitagliptin may include nasopharyngitis, upper respiratory tract infection, and headache [1].
How does Segluromet compare to other diabetes medications?
Segluromet offers a combination therapy that can be more effective than monotherapy for some patients with type 2 diabetes. Its two components target different mechanisms to lower blood glucose. Comparisons to other specific diabetes medications, such as GLP-1 receptor agonists or SGLT2 inhibitors, would depend on individual patient needs and treatment goals [1].
Who manufactures Segluromet?
Segluromet is manufactured by Merck & Co. [1].
Sources:
[1] https://www.merck.com/
[2] https://drugpatentwatch.com/